The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections.

Ibrahim H Babikir, Elsir A Abugroun, Naser Eldin Bilal, Abdullah Ali Alghasham, Elmuataz Elmansi Abdalla, Ishag Adam
Author Information
  1. Ibrahim H Babikir: College of Medical Laboratory Sciences, Microbiology Department, University of Khartoum, Khartoum, Sudan. almakibrahim@hotmail.com.
  2. Elsir A Abugroun: Faculty of Medical Laboratory Sciences, University of Science and Technology, Omdurman, Sudan.
  3. Naser Eldin Bilal: Khartoum University Central Research Laboratory, University of Khartoum, PO Box 321, Khartoum, Sudan.
  4. Abdullah Ali Alghasham: College of Medicine, Qassim University, Buraydah, Qassim, Kingdom of Saudi Arabia.
  5. Elmuataz Elmansi Abdalla: College of Medicine, Qassim University, Buraydah, Qassim, Kingdom of Saudi Arabia.
  6. Ishag Adam: College of Medicine, Qassim University, Buraydah, Qassim, Kingdom of Saudi Arabia.

Abstract

BACKGROUND: The defense mechanisms of the urinary tract are attributed mainly to the innate immune system and the urinary tract urothelium which represent the first line of defense against invading pathogens and maintaining sterility of the urinary tract. There are only a few publications regarding cathelicidin (LL-37) and a urinary tract infection (UTI). This study was done to investigate the plasma and urine levels of human LL-37 in patients with UTI.
METHODS: A case-control study was conducted at Omdurman Hospital, Sudan during the period from August 2014 to May 2017. The cases were patients with confirmed UTI and the controls were healthy volunteers without UTI. Sociodemographic and clinical data were obtained from each participant using questionnaires. Urine cultures and antimicrobial susceptibility were tested. Plasma and urine levels of LL-37 were determined using an enzyme-linked immunosorbent assay (ELISA) kit. SPSS (version 16.0) was used for analyses.
RESULTS: Cases and controls (87 in each arm) were matched according to their basic characteristics. Compared with controls, the median (inter-quartile) LL-37 level in plasma [2.100 (1.700-2.700) vs. 1.800 (1.000-2.200) ng/ml, P = 0.002] and in urine [0.900 (0.300-1.600) vs. 0.000 (0.000-1.000) ng/mg creatinine, P < 0.001] was significantly higher in cases. There was no significant difference in the median plasma [2.1 (1.7-2.9) vs. 2.000 (1.700-2.400) ng/ml, P = 0.561] and urine [0.850 (0.275-2.025) vs. 0.900 (0.250-1.350) ng/mg creatinine, P = 0.124]. The uropathogenic Escherichia coli (UPEC) was the predominant isolate, n = 38 (43.7%). LL-37 levels between the E. coli isolates and the other isolated organisms. There was no significant correlation between plasma and urine LL-37 levels (r = 0.221), even when the data of the cases were analyzed separately.
CONCLUSION: LL-37 is notably increased among patients with UTI compared with normal control subjects. Severity of UTI increases the levels of LL-37. The increased level was not only in the patient's urine, but has also been observed in the patient's plasma. Detection of increased levels of LL-37 could help to differentiate subjects with suspected UTI. Accordingly, LL-37 could act as a good marker for diagnosing UTIs.

Keywords

References

  1. J Clin Invest. 1998 Apr 15;101(8):1633-42 [PMID: 9541493]
  2. Blood. 2001 Jun 15;97(12):3951-9 [PMID: 11389039]
  3. Nat Rev Nephrol. 2015 Nov;11(11):642-55 [PMID: 26149835]
  4. Nat Rev Urol. 2011 Jul 12;8(8):449-68 [PMID: 21750501]
  5. Ann Clin Microbiol Antimicrob. 2011 Jan 18;10:2 [PMID: 21244660]
  6. Curr Protein Pept Sci. 2005 Feb;6(1):23-34 [PMID: 15638766]
  7. Science. 1998 Nov 20;282(5393):1494-7 [PMID: 9822381]
  8. Nat Rev Urol. 2010 Dec;7(12):653-60 [PMID: 21139641]
  9. Curr Pharm Des. 2002;8(9):779-93 [PMID: 11945171]
  10. Int J Gen Med. 2011;4:333-43 [PMID: 21674026]
  11. Postgrad Med J. 2005 Feb;81(952):83-6 [PMID: 15701738]
  12. Ann Clin Microbiol Antimicrob. 2015 Apr 21;14:26 [PMID: 25896611]
  13. J Urol. 2009 Jul;182(1):21-8 [PMID: 19447447]
  14. Nature. 2002 Jan 24;415(6870):389-95 [PMID: 11807545]
  15. Eur J Clin Invest. 2008 Oct;38 Suppl 2:21-8 [PMID: 18826478]
  16. Int Immunol. 2011 Mar;23(3):185-93 [PMID: 21393634]
  17. Blood. 2000 Nov 1;96(9):3086-93 [PMID: 11049988]
  18. Nat Rev Immunol. 2003 Sep;3(9):710-20 [PMID: 12949495]
  19. Drugs Future. 2010 Mar;35(3):197 [PMID: 20495663]
  20. Kidney Int. 2000 May;57(5):2004-10 [PMID: 10792619]
  21. Infect Immun. 2014 Apr;82(4):1572-8 [PMID: 24452682]
  22. Rev Med Interne. 2004 Sep;25(9):629-35 [PMID: 15363618]
  23. Pediatr Nephrol. 2014 Jul;29(7):1139-49 [PMID: 23732397]
  24. J Pediatr. 1986 Sep;109(3):416-21 [PMID: 3746529]
  25. Nat Med. 2006 Jun;12(6):636-41 [PMID: 16751768]
  26. J Clin Invest. 1968 Dec;47(12):2689-700 [PMID: 4881768]
  27. Clin Diagn Lab Immunol. 2002 Sep;9(5):972-82 [PMID: 12204946]
  28. Curr Issues Mol Biol. 2005 Jul;7(2):179-96 [PMID: 16053249]
  29. Infect Immun. 2002 Jun;70(6):3053-60 [PMID: 12010997]
  30. Int J Antimicrob Agents. 2004 Dec;24(6):536-47 [PMID: 15555874]
  31. J Clin Res Pediatr Endocrinol. 2016 Sep 1;8(3):325-9 [PMID: 27180947]
  32. Annu Rev Immunol. 1986;4:389-417 [PMID: 3518747]
  33. Infect Immun. 1995 Apr;63(4):1291-7 [PMID: 7890387]
  34. Int Immunol. 2006 Dec;18(12):1729-36 [PMID: 17041145]
  35. Lancet. 1999 Jan 2;353(9146):7-8 [PMID: 10023942]
  36. Kidney Int. 2004 Mar;65(3):791-7 [PMID: 14871399]
  37. J Am Soc Nephrol. 2007 Nov;18(11):2810-6 [PMID: 17942949]
  38. J Invest Dermatol. 2003 May;120(5):810-6 [PMID: 12713586]
  39. J Mol Med (Berl). 2008 Jan;86(1):37-47 [PMID: 17805504]
  40. J Leukoc Biol. 2004 Jan;75(1):39-48 [PMID: 12960280]

MeSH Term

Adult
Aged
Antimicrobial Cationic Peptides
Case-Control Studies
Cathelicidins
Child
Creatinine
Enzyme-Linked Immunosorbent Assay
Female
Hospitals
Humans
Linear Models
Male
Sudan
Urinary Tract Infections
Uropathogenic Escherichia coli

Chemicals

Antimicrobial Cationic Peptides
Cathelicidins
Creatinine

Word Cloud

Created with Highcharts 10.0.0LL-37UTI0tracturinelevels1urinaryplasmavspatientscasescontrolsP = 0000coliincreaseddefensecathelicidinstudyhumanSudandatausingantimicrobialmedianlevel[2700-2ng/ml[0900ng/mgcreatininesignificant2Esubjectspatient'speptideinfectionsBACKGROUND:mechanismsattributedmainlyinnateimmunesystemurotheliumrepresentfirstlineinvadingpathogensmaintainingsterilitypublicationsregardinginfectiondoneinvestigateMETHODS:case-controlconductedOmdurmanHospitalperiodAugust2014May2017confirmedhealthyvolunteerswithoutSociodemographicclinicalobtainedparticipantquestionnairesUrineculturessusceptibilitytestedPlasmadeterminedenzyme-linkedimmunosorbentassayELISAkitSPSSversion16usedanalysesRESULTS:Cases87armmatchedaccordingbasiccharacteristicsComparedinter-quartile100700800000-2200002]300-1600000-1P < 0001]significantlyhigherdifference7-29400561]850275-2025250-1350124]uropathogenicEscherichiaUPECpredominantisolaten = 38437%isolatesisolatedorganismscorrelationr = 0221evenanalyzedseparatelyCONCLUSION:notablyamongcomparednormalcontrolSeverityincreasesalsoobservedDetectionhelpdifferentiatesuspectedAccordinglyactgoodmarkerdiagnosingUTIsimpactAntimicrobialCathelicidinUrinaryUropathogenicVitekSystem

Similar Articles

Cited By (15)